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Abstract
Ebolaviruses cause hemorrhagic fever with up to 90% lethality and in fatal cases, are characterized by early suppression of
the host innate immune system. One of the proteins likely responsible for this effect is VP24. VP24 is known to antagonize
interferon signaling by binding host karyopherin a proteins, thereby preventing them from transporting the tyrosine-
phosphorylated transcription factor STAT1 to the nucleus. Here, we report that VP24 binds STAT1 directly, suggesting that
VP24 can suppress at least two distinct branches of the interferon pathway. Here, we also report the first crystal structures of
VP24, derived from different species of ebolavirus that are pathogenic (Sudan) and nonpathogenic to humans (Reston).
These structures reveal that VP24 has a novel, pyramidal fold. A site on a particular face of the pyramid exhibits reduced
solvent exchange when in complex with STAT1. This site is above two highly conserved pockets in VP24 that contain key
residues previously implicated in virulence. These crystal structures and accompanying biochemical analysis map
differences between pathogenic and nonpathogenic viruses, offer templates for drug design, and provide the three-
dimensional framework necessary for biological dissection of the many functions of VP24 in the virus life cycle.
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Introduction
The ebolaviruses and marburgviruses are enveloped, non-
segmented, negative-strand RNA viruses that belong to the family
Filoviridae. There are five antigenically distinct ebolaviruses that
are ,40% different in amino acid sequence, and are each named
after the location of the outbreak during which they were first
identified: Zaire (now known simply as Ebola virus or EBOV),
Sudan virus (SUDV), Taı ¨ Forest virus (TAFV), Reston virus
(RESTV) and Bundibugyo virus (BDBV). Marburgviruses and
most ebolaviruses cause severe hemorrhagic fever in both humans
and nonhuman primates, with fatality up to 90%. The exception is
RESTV, which appears to be non-pathogenic in humans,
although it remains pathogenic to non-human primates [1,2].
Reasons why RESTV has not caused disease in humans are
unclear. However, microarray analyses have shown that RESTV
has a reduced ability to suppress host immune responses [3].
For the pathogenic ebolaviruses, early suppression of host
interferon (IFN) production and signaling plays a decisive factor in
disease outcome [4,5]. Two proteins of the ebolaviruses are used in
this strike. The protein VP35 blocks production of IFN-a/b [6] by
binding dsRNA, a key hallmark of viral infection, and shielding it
from recognition by host immune sensors such as RIG-I and
MDA-5 [7,8]. By contrast, the protein VP24 inhibits signaling
downstream of both IFN-a/b and IFN-c by sequestering
karyopherin a proteins (a1, a5 and a6) [9]. Binding to these
proteins prevents them from shuttling otherwise activated,
phosphorylated STAT1 to the nucleus [9–11].
STAT1 belongs to the STAT family of transcription factors, is a
key mediator of the IFN response pathway [12–14] and plays an
essential role in the immune response to viruses [15–17]. STAT1
predominately exists in an unphosphorylated form (U-STAT1).
Numerous immune factors like type I and type II interferon
[14,18,19], interleukins like IL-6 and IL-10 [20–23], growth
factors [20,24–26], angiotensin [27], and TNFa [28] cause
STAT1 to be phosphorylated (P-STAT1) by the Janus family
kinases (JAKs). Upon phosphorylation, P-STAT1 either dimerizes
or forms a complex with IFN a/b-stimulated gene factor 3
(ISGF3) [18,29,30], and is subsequently transported to the nucleus
via karyopherin a proteins where it regulates genes involved in the
immune response [31–33].
The importance of STAT1 to the antiviral response is
underlined by the fact that viruses (and other microbes) have
evolved proteins that inhibit every step of STAT1 activation [14].
As examples, the V proteins of Nipah and Hendra viruses and the
P protein of rabies virus directly bind to P-STAT1 to sequester it
in the cytoplasm [34–36]. By contrast, the P protein of measles
virus and an unidentified protein of human metapneumovirus
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protein of vaccinia virus and the NS5 protein of Japanese
encephalitis virus actively dephosphorylate the P-STAT1 complex
[39,40], and the V protein of mumps causes ubiquitination and
degradation of P-STAT1 [41]. The VP24 protein of ebolavirus, in
yet another mechanism, prevents nuclear translocation of P-
STAT1 by binding to the karyopherin a transporter proteins [9–
11].
In addition to its role in interferon antagonism, ebolavirus VP24
has also been proposed to associate with membranes [42,43], and
is important for assembly and function of the viral ribonucleo-
protein complex (RNP) [44–46], where VP24 binds to the viral
nucleoprotein NP [45]. VP24 has no sequence homology to any
known protein and the molecular mechanisms by which VP24
suppresses immune signaling and contributes to RNP assembly are
poorly understood.
Here, we demonstrate that VP24 also binds directly to STAT1
itself, present the first X-ray crystal structures of VP24 from both
Sudan and Reston viruses, and map a possible site of STAT1
interaction on the VP24 crystal structure by deuterium exchange
mass spectrometry (DXMS). The biochemical and structural
analysis presented here identifies a new function by which VP24
may contribute to and/or prolong innate immunosuppression, and
provides the necessary three-dimensional templates for under-
standing the multiple roles of VP24 in the ebolavirus life cycle and
design of antiviral compounds against them.
Results
VP24 binds purified STAT11–683
Other negative-sense viruses encode proteins that suppress
innate immune signaling by direct interaction with STAT1. VP24
was previously known to indirectly affect STAT1 by binding
karyopherins to prevent them from translocating phosphorylated
STAT1 (P-STAT1). However, we wondered if VP24 could play a
more direct role as well. To answer this question, we performed an
ELISA to test binding of purified Ebola virus VP24 or Sudan virus
VP24 to purified STAT11–683 (truncated prior to its phosphory-
lation site at Tyr701). BSA was used as a negative control. Indeed,
VP24 is able directly associate with STAT11–683 (Figure 1).
Although it remains to be determined if VP24 binds equally well to
full-length P-STAT1 and U-STAT1, the initial finding that VP24
Figure 1. Purified truncated VP24s, SUDV1–233 and EBOV1–233, were determined to bind to purified STAT11–683 using an ELISA
assay. Either SUDV1–233 or EBOV1–233 was coated onto the ELISA plate at 0.01 mg/ml as described in the Materials and methods section. Upon
subsequent incubation with STAT11–683, binding was detected with HRP conjugated secondary antibody and O.D. was read at 450 nm. BSA was used
as a negative control.
doi:10.1371/journal.ppat.1002550.g001
Author Summary
Ebolaviruses cause severe hemorrhagic fever that is
exacerbated by immediate suppression of host immune
function. VP24, one of only eight proteins encoded by
ebolaviruses, functions in virus replication and assembly,
and is thought to contribute to immune suppression by
binding to a certain class of molecules called karyopherins
to prevent them from transporting a transcription factor
termed STAT1. Here we report that VP24 is also able to
directly bind STAT1 by itself, and thereby likely contributes
to immune suppression by an additional mechanism.
Analysis of these multiple roles of VP24 and design of
drugs against them have been hindered by the lack of
structural information on VP24 and its lack of homology to
any other known protein. Hence, here we also present X-
ray structures of VP24 derived from two different
ebolavirus species that are pathogenic and nonpathogenic
to humans. These structures and accompanying deuterium
exchange mass spectrometry identify the likely binding
site of STAT1 onto VP24, map sites that are conserved or
differ between pathogenic and nonpathogenic species,
and provide the critical 3D templates by which we may
dissect and interpret the many roles that VP24 plays in the
virus life cycle.
Structures of the Ebolavirus Protein VP24
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which VP24 might contribute to innate immune suppression.
VP24 adopts a novel ‘‘pyramidal’’ fold
In order to provide 3D templates for understanding VP24 and
its many roles in immune evasion, replication and assembly, we
crystallized VP24 from Sudan virus (two versions crystallized:
SUDV1–233 and SUDV11–233) and Reston virus (one version
crystallized: RESTV11–237) (Figure S1a). We determined the
structure of SUDV11–233 at 2.1 A ˚ resolution by multiwavelength
anomalous diffraction (MAD) using selenomethionine-incorpo-
rated protein expressed recombinantly in E. coli. We subse-
quently determined structures of SUDV1–233 and RESTV11–237
by molecular replacement, both at 2.0 A ˚ resolution (Table 1).
VP24 adopts a compact, single domain, a/b structure of novel
fold (DaliLite v.3 [47]). The overall shape of VP24 resembles a
triangular pyramid of dimensions 73 A ˚630 A ˚630 A ˚. The three
faces of the pyramid are numbered 1, 2 and 3 (Figures 2 and S1b).
A collection of a helices (a1 and a5-10) and a small, three-
stranded, antiparallel b sheet (b1-3) form the top of the pyramid
with the N-terminus at the apex. A five-stranded antiparallel b
sheet (b4-8) forms the center, while a second collection of a helices
(a2-4) forms the base. Portions of the C-terminal region resemble
prior de novo predictions: as predicted, helices 5–8 are indeed
observed, helix 8 is quite long, and a b sheet exists at the base of
the structure. Differences between the prediction and the
experimental structure are that a three-stranded sheet was
predicted, but a five-stranded sheet is observed [48] and that an
armadillo repeat-type domain structure was predicted, but no such
domain is observed in VP24.
Two adjacent, conserved pockets
VP24 is 63% identical among ebolaviruses and ,30% identical
between ebola- and marburgviruses. Regions of high sequence
conservation congregate on Faces 1 and 3 (Figures 3 and S2a). The
conserved center of Face 1 is formed by a5, b3, b5a n db8. The
conserved center of Face 3 is formed by a5, a8, b5a n db6. The base
ofeachofFaces1and 3alsocontainsaconservedcavity,and thetwo
cavities are located adjacent to each other on the protein surface.
The Face 1 cavity is hydrophobic and is 14614612 A ˚ in size
(Figure 4a). The interior of the cavity is lined with five absolutely
conserved leucine residues: L57, L75, L79, L198, and L221. The
entrance to the hydrophobic cavity (11 A ˚ wide) appears to be
gated by two residues (Y172 and M71) that point away from each
other in RESTV VP24 but toward each other in SUDV VP24,
appearing to block the hydrophobic cavity (Figure S3a–S3b).
Table 1. Data collection and refinement statistics.
Crystals SUDV11–233 (Native) SUDV11–233 (Sepeak) SUDV11–233 (Seinflection) SUDV1–233 (Native) RESTV11–237 (Native)
Data collection
Space group P3121 P3121 P3121 P3121 P1211
Cell dimensions:
a, b, c (A ˚) 61.1, 61.1, 126.8 61.2, 61.2, 106.9 61.3, 61.3, 106.7 61.1, 61.1, 130.4 38.4, 103.9, 59.8
a, b, c (u) 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120 90, 94, 90
Resolution (A ˚) 50–2.1 50–2.2 50–2.3 50–2.0 50–2.0
Solvent content (%) 63 63 63 63 63
Rsym
a (%) 0.075 0.065 0.095 0.068 0.046
I/s(I)
b 8.3 (1.6) 9.5 (2.3) 6.0 (1.8) 8.4 (1.3) 21 (1.9)
Completeness (%) 95.8 99.6 100.0 99.6 98.7
Redundancy 8.3 5.7 5.7 10.5 3.0
Refinement
Resolution (A ˚) 33–2.1 34–2.0 31–2.0
No. reflections 16550 18009 29379
Rwork/Rfree 23.4/27.0 22.0/26.3 18.6/22.7
No. of atoms:
Protein 1592 1727 3166
Water 46 78 110
R.m.s deviations
Bond lengths (A ˚) 0.014 0.015 0.013
Bond angles (u) 1.102 1.106 1.047
Ramachandran plot
c
Most Favored 93.1 92.7 92.3
Additionally Allowed 6.9 7.3 7.4
Generously Allowed 0.0 0.0 0.3
Disallowed 0.0 0.0 0.0
aR linear=g |( I 2,I.)|/g (I).
bValues in parentheses refer to the last shell.
cAs defined in MolProbity.
doi:10.1371/journal.ppat.1002550.t001
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and is hydrophilic rather than hydrophobic (Figure 4b). Five
residues that are conserved across all filoviruses (S178, E180, I189,
T191, and E200) populate the base of the cavity. Six conserved
residues circle the rim (P77, T193, K206, and M209 are conserved
across all ebolaviruses; H78 and N82 are conserved across all
Figure 2. Alternate views of VP24 secondary structure. The overall shape of VP24 resembles a three-sided pyramid with Faces 1 (a), 2 (b), and
3( c) as illustrated. Only SUDV1–233 is shown for clarity. Arrows indicate conserved pockets on Faces 1 and 3.
doi:10.1371/journal.ppat.1002550.g002
Figure 3. Conservation map of VP24. (a) Sequence conservation in VP24 among Ebola (Zaire), Sudan, Reston, Taı ¨ Forest, and Bundibugyo viruses
mapped onto the structure of SUDV1–233.( b) Sequence conservation in VP24 between ebola- and marburgviruses. Sequence conservation is mapped
as navy (completely conserved) to red (least conserved). A hydrophobic cavity in Face 1 and a polar cavity in Face 3 are indicated by arrows. Least
conserved regions are clustered around Face 2. Sequence identity is calculated using Homolmapper [83]. Figures are illustrated using SUDV1–233.
doi:10.1371/journal.ppat.1002550.g003
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(L75, F76, and L198) line the edge between the Face 1 and Face 3
cavities and are accessible from either side.
Serial passage studies to confer lethality of EBOV to rodents
resulted in five mutations in VP24 (H186Y, T187I, M71I, L147P
[49], and T50I [50]), four of which lie in or near these cavities.
H186 (Y186 in SUDV), T187 (A187 in SUDV) and T50 (N50 in
SUDV and S50 in RESTV) lie on the rim of the Face 3 cavity
(Figure 4c). M71 forms the ‘‘gate’’ to the Face 1 cavity. The fifth
residue, L147 (M147 in SUDV), is located toward the top of the
pyramid in helix a8, and is accessible from Face 3. L147 is thought
to be involved in karyopherin a binding (Figure 4c).
Residues implicated in karyopherin a binding
In infected cells, EBOV VP24 binds to karyopherin a1, a5, and
a6 to prevent translocation of P-STAT1 into the nucleus [10].
Previous mutagenesis studies have shown VP24 residues W42 and
142–146 to be critical for karyopherin a1 binding [11]. W42 is
buried in the interior of the single globular VP24 fold. Hence,
mutagenesis of W42 most likely compromised the VP24 structure
and affected karyopherin a1 affinity indirectly (Figure 4c). By
contrast, residues 142–146 are exposed to solvent and would be
available to directly bind karyopherin a1. As previously described,
an L147P mutation (a8, adjacent to residues 142–146) in EBOV
VP24 increases virulence in guinea pigs [49].
Unlike the ebolaviruses, the VP24 protein of Marburg virus
does not block interaction of P-STAT1 with karyopherin a1 [51].
W42 is conserved between ebola- and marburgviruses, but
residues 142–147 are not. Residues 142–147 are K(E/D)QLS(L/M)
in the ebolaviruses but are GIYLTS in the marburgviruses (Figure
S2a).
Interaction with STAT11–683
Deuterium exchange mass spectrometry (DXMS) is able to
rapidly map footprints of protein-protein binding sites and offers
a broader picture than analysis of point mutants alone [52–56].
In this method the ability of peptide amide hydrogens to freely
and reversibly exchange with solvent deuterium is measured.
Hydrogens for which mobility is restricted (by conformational
anchoring and/or ligand binding) exchange more slowly.
Hydrogens for which mobility is unrestricted (conformational
mobility) exchange more rapidly. We performed comparative
DXMS studies on VP24 alone and VP24 in complex with
STAT11–683. The resulting exchange maps identify some peptidic
regions of VP24 that exchange with solvent less rapidly when in
complex with STAT1 (possible binding sites), and other regions
of VP24 that exchange with solvent more rapidly when in
complex with STAT1, perhaps due to conformational change
and increased mobility.
In the presence of purified STAT11–683, VP24 peptidic regions
96–98 and 106–121 demonstrate slower H/D exchange kinetics,
suggesting a site of protein-protein interaction (Figure 5). By
contrast, VP24 peptidic regions 71–79 and 181–198 demonstrated
increased H/D exchange in the presence of STAT11–683,
suggesting possible conformational change with enhanced flexi-
bility. The faster exchanging peptides 71–79 and 181–198 map to
helix a3–4 and strands b5–7, respectively. Both of these secondary
structure elements exist in the polar cavity at the bottom of Face 3
and are highly conserved across the filoviruses. The slower-
exchanging peptides 96–98 and 106–121 map to helices a5 and
a6, also on the conserved portion of Face 3. Helices a5 and a6 are
amphipathic in nature: the hydrophobic side of each coil points
into the core of VP24. Hydrophilic residues extend to the surface
of Face 3. The C-terminal region of a5 is negatively charged and
the N-terminal portion of a6 is positively charged.
Sites in VP24 that differ between ebolaviruses that are
pathogenic and nonpathogenic to humans
Mapping of sequence differences between RESTV and the
major pathogenic ebolaviruses (SUDV and EBOV) onto the
RESTV11–237 structure indicates that RESTV VP24 differs in
,30 sites (Figure S4). One of these sites, a cluster of residues L136,
R139 and S140 (in RESTV), is next to the 142–146 loop, which is
important for binding karyopherin a1 [11] (Figure S4 and Figure
Figure 4. Key sites of VP24. (a) The hydrophobic cavity at the base of Face 1. Leucines 57, 75, 79, 198, and 221 are completely conserved across
the filoviruses. Electrostatic surface calculated with APBS [84] is shown inset, with Y172 and M71 drawn in magenta. (b) Polar cavity at the base of
Face 3. Residues Y186 and A187 are conserved across all ebolaviruses except SUDV. Residues P77, T193, K206, and M209 are conserved among
ebolaviruses and the remaining residues are conserved across both ebola- and marburgviruses. Inset is calculated with APBS. Color scale ranges from
26kT/z (bright red) to +6kT/z (dark blue). (c) Residues important for virulence are colored navy; residues important for binding karyopherin Æ1 are
colored cyan. Figures are illustrated using SUDV1–233.
doi:10.1371/journal.ppat.1002550.g004
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L107, H109, T116 and G120 that exists within the 106–121
polypeptide that exhibits decreased H/D exchange in complex
with STAT11–683 and may serve as a STAT1 binding site. A third
site, the cluster of residues S184, T185, H186, T187 and F197, lies
in the 181–198 polypeptide that undergoes enhanced H/D
exchange in the presence of STAT11–683. A fourth site, V201,
lies next to this region. A fifth site, residue S50, was previously
implicated in a serial passage study to confer lethality to mice [50].
Purified VP24 is monomeric
Previous studies analyzing VP24 in the context of whole cell
lysate found that the majority of VP24 was monomeric. A smaller
portion appeared as a high molecular weight aggregate and a
smaller oligomer, likely a tetramer [42,43]. We performed gel
filtration analysis of purified, full-length SUDV, RESTV and
EBOV VP24 (whether produced in E. coli or 293T cells) and find
that purified VP24 from all three viruses is monomeric in solution
(Figure S5). The significance of the multimerized portion observed
in cell lysate is unclear. Perhaps a portion of VP24 homo-
oligomerizes in cells, or perhaps factors present in whole-cell lysate
are needed for VP24 to form oligomers.
Crystal packing can sometimes illustrate biologically relevant
assemblies, but no tetrameric or other higher oligomeric
interactions are observed in crystals of SUDV or RESTV VP24.
One pairwise VP24-VP24 interaction is conserved in the crystal
packing between the SUDV (P3121) and RESTV VP24 (P1211)
structures, although it is currently unclear if it is biologically
relevant (Figure S3c). This interaction involves a1, b1–3 and the
N-terminal region of a8, and buries residue L147 that was
previously implicated for virulence [49], although 142–146 remain
solvent exposed. Another crystal lattice interaction observed in
both RESTV and SUDV structures involves packing of the
hydrophobic N-terminal regions of VP24 into the Face 3 pocket of
a neighboring molecule (Figure S3d–S3e).
Discussion
The crystal structures presented here illustrate the novel,
pyramidal fold of ebolavirus VP24. In this work, we have also
identified STAT1 as a new binding partner of VP24 and have
used DXMS to suggest that residues 96–98 and 106–121 are
contained in a putative binding site for STAT11–683.
Although VP24 differs by 37% in protein sequence among the
ebolaviruses, there are large patches of complete conservation on
Faces 1 and 3 including the two pockets in these faces at the base
of the pyramid. Several residues, found in serial passage studies to
increase virulence of Ebola virus, map to these sites, although the
precise role of the conserved pockets remains unclear. Another
residue identified in these studies maps to a site thought to be
involved in binding host karyopherin a proteins. The putative
STAT1-binding site identified by DXMS lies in the conserved
region of Face 3 and is distinct from the site proposed to interact
with karyopherin a1.
Crystal structures presented here include VP24 from an
ebolavirus that is pathogenic to humans (Sudan virus; SUDV)
and VP24 from an ebolavirus that thus far, appears nonpatho-
genic to humans (Reston virus; RESTV), although it is lethal to
nonhuman primates. The overall folds of SUDV and RESTV
VP24 are similar, as expected (r.m.s.d. of 0.81 A ˚; also see Figure
S2b for structural alignment). Specific viral or host factors
responsible for the differences in pathogenicity between these
viruses have not yet been identified, but it has been proposed that
RESTV has a diminished ability to suppress cellular IFN-a/b
and IFN-c responses [3]. Residues in VP24 that are unique to
RESTV often colocalize with residues that appear to be
important for karyopherin and STAT1 binding, or are important
for virulence in rodents through an unknown mechanism. The
location of these RESTV-specific amino acids invites speculation
that RESTV VP24 and EBOV/SUDV VP24 could potentially
bind immune factors like karyopherins and STAT1 with differing
affinity.
Here we have found that purified VP24 binds directly to
purified STAT1 truncated prior to its phosphorylation site. In a
healthy cell, STAT1 exists in an unphosphorylated form. During
viral infection, production of interferons and cytokines leads to
phosphorylation and homodimerization of STAT1 or hetero-
dimerization of STAT1 with its b isoform. The resulting P-STAT1
dimer is then transported by karyopherin a proteins into the
nucleus where it controls transcription-regulated genes. Interest-
ingly, this P-STAT1 may have a different oligomeric structure
than U-STAT1 [57,58].
U-STAT1 is not inactive, but rather, is also important in
regulation of the immune response. Interestingly, U-STAT1
functions in different ways than its phosphorylated counterpart.
U-STAT1 is transported into the nucleus [59,60] by direct
involvement with nucleoporins [61], and does not need transport
by karyopherins. In the nucleus, U-STAT1 activates and prolongs
the expression of a number of IFN-induced immune regulatory
genes like IFI27, IFI44, OAS, and BST2 [62]. U-STAT1
functions independently of P-STAT1 and the set of genes on
which it operates can be distinct from those of P-STAT1 [59]. U-
STAT1 and P-STAT1 also differ temporally: the phosphorylation
of STAT1 lasts for several hours, but the presence of U-STAT1
persists for several days [62,63]. In this way, U-STAT1 is likely to
be able to prolong an antiviral state.
Hence, both P-STAT1 and U-STAT1 play multiple roles in
antiviral defense, and may play somewhat different roles in
different cell types. By affecting both P-STAT1 (by binding
karyopherins and/or possibly by forming a karyopherin-STAT1-
VP24 tertiary complex) and U-STAT1 (if it binds full-length U-
STAT1 as well as unphosphorylated STAT11–683), VP24 could
prevent or dampen antiviral responses through multiple routes.
The combination of both ebolavirus VP24 and ebolavirus VP35
(which acts upon virally induced dsRNA) in the infected cell
offers greater coverage of the different pathways by which
antiviral responses occur. Interestingly, plasmocytoid dendritic
cells (pDCs), which are major producers of type I interferon [64],
Figure 5. Results of deuterium exchange mass spectrometry analysis of SUDV1–233 in complex with STAT11–683. (a) Exchange results
are mapped onto SUDV1–233. Peptidic segments colored blue exhibit slowing of H/D exchange kinetics, while segments colored red exhibit an
increase in H/D exchange kinetics. Segments colored white exhibit no change. Segments colored grey were not observed in these experiments. (b)
Conservation map of SUDV1–233. Circles indicate sites of change in H/D exchange upon binding to STAT11–683. Green arrows denote the position of
the Face 3 cavity. Deuterium exchange mass spectrometry of (c) SUDV1–233 alone and (d) in complex with STAT11–683 illustrated as sequence
representations. Each block indicates peptidic regions defined by overlapping peptides and is consist of three time points (10 s, 100 s, and 1000 s).
Deuteration levels at each time point are illustrated as blue (,10% deuteration) to red (.90% deuteration). Grey indicates residues that are not
observed. Box indicates regions of either speeding up or slowing down of deuteration upon binding to STAT11–683. The average standard deviation of
deuterium incorporation is 1.5% between replicates.
doi:10.1371/journal.ppat.1002550.g005
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exert a synergistic effect, and/or VP24 functions in cells where
VP35 does not.
Although VP24 is key to the virulence of ebolaviruses, little is
known about it due, in part, to the lack of any structural
information on VP24 and the lack of any homology to other
known proteins. We have shown that purified VP24 and purified
STAT11–683 interact. The functional manifestation of this
interaction remains to be determined. Does VP24 target STAT1
for degradation, sequester it in the cytoplasm or in high-molecular
weight complexes, or prevent its phosphorylation? Does VP24 also
bind P-STAT, and does it exhibit a preference for one form over
the other? Does VP24 bind other STATs in addition to STAT1?
Intriguingly, STAT3 shares about 72% sequence homology with
STAT1 [66], and operates in intestinal epithelia where it regulates
mucosal wound healing [67]. Inactivation of STAT3 may
contribute to colitis and clinical manifestations of Ebola virus
infection like abdominal pain and bloody stools [68,69]. Another
question is if any of the mapped differences between RESTV and
EBOV/SUDV VP24 are linked to or are responsible for the
differences in pathogenicity in humans. The structures presented
here provide a framework for answering these and other questions
about the multiple roles of VP24 in the viral lifecycle. These
structures also provide the much-needed templates for design of
antiviral drugs to inhibit key functions of VP24 in transcription,
replication, and immunosuppression.
Materials and Methods
VP24 expression and purification
VP24 from Sudan virus (SUDV1–233 and SUDV11–233 in
pET46 Ek/LIC vector) was expressed in E. coli Rosetta-gami
2(DE3)pLysS cells. Truncation of the C terminus permitted
protein solubility in the absence of detergents. The N-terminal
truncation used in the first SUDV constructs was based on general
construct screening. Cultures were grown in LB medium
supplemented with ampicillin (100 mgm l
21), and expression was
induced by the addition of 0.5 mM IPTG at 16uC. Harvested cells
from overnight induction were resuspended in lysis buffer (50 mM
NaH2PO4, pH 8.0, 0.3 M NaCl, 10 mM imidazole) for lysis at
25,000 psi using a Microfluidizer processor. The lysed mixture
was then centrifuged for 50 minutes at 16,000 r.p.m. in a JA-17
rotor (Beckman Coulter). The supernatant was loaded on a
HisTrap FF crude column (GE Healthcare) with a step gradient of
30 mM and 500 mM imidazole in lysis buffer. SUDV1–233 and
SUDV11–233 VP24 were further purified by size exclusion on a
HiLoad 16/60 Superdex 75 prep grade column (Amersham
Pharmacia) in 10 mM Tris-HCl, pH 8.0, 0.3 M NaCl.
Full-length SUDV VP24 was expressed and purified essentially
as above. Addition of 2.5 mM CHAPS throughout the purification
enhanced solubility, and a Superdex 200 column was used for size
exclusion.
Selenomethionine-incorporated SUDV11–233 was expressed and
purified as follows: 2 mL of an overnight culture in LB broth was
transferred into 20 mL LB containing 0.4% glycerol and
100 mgm l
21 ampicillin. After a one-hour incubation, the cells
were harvested by centrifugation at 3000 r.p.m. and resuspended
in 20 mL M9 minimal media, then transferred into 1 L M9 media
containing ampicillin. At OD600 0.4, L-isoleucine, L-leucine, L-
lysine, L-phenylalanine, L-threonine, and L-valine were added to
final concentrations of 100 mg/L each, prior to addition of L-
selenomethionine (to 60 mg/L). The culture was induced with
IPTG after 15 min. Cells were harvested after 4 hr and purified as
described above.
Full-length SUDV (in pTriEx 5 vector (Novagen)) was also
transiently expressed in mammalian HEK293T cells in a five-layer
CellStack (corning). The cells were transfected at 60% confluency
with 420 mg of DNA and 1.2 mg of PEI diluted in 42 ml of PBS.
The PEI mixture was incubated at room temperature for 20 min.
before adding to the cells. After 48 hours, cells were freeze-thawed
three times and lysed in 10 mM Tris-HCl, pH 8.0, 0.3 M NaCl.
Protein was affinity purified with strep-tactin superflow beads
(Qiagen), then further purified by size exclusion on a Superdex
200 10/300 GL (GE Healthcare). 10 ml of the peak fraction was
run on SDS-PAGE, and probed by Western blot with an anti-strep
antibody.
All SUDV VP24 proteins contain a valine to alanine
substitution at position 22 from the GenBank deposited sequence.
Residue 22 is on helix a1 and is buried within the structure (Figure
S6). The Sudan virus (strain Boniface) replicon was a gift of Dr.
John M. Dye (USAMRIID). Oligonucleotides were purchased
from Valuegene Inc.
Full-length Ebola virus (Zaire, EBOV) VP24 and both full-
length and N- and C-terminally truncated Reston (RESTV) virus
VP24 were expressed and purified in E. coli as previously
described. Full-length EBOV VP24 was cloned into the pET46
Ek/LIC vector from cDNA that was a gift from Dr. Viktor
Volchkov (Claude Bernard Universite ´ de Lyon 1). cDNA for
RESTV VP24 was synthesized by GenScript (Piscataway, NJ).
Both full length RESTV and RESTV11–237 were subcloned into
pET46 Ek/LIC for expression.
STAT1 expression and purification
Truncated, unphosphorylated STAT11–683 (human) in a pET46
Ek/LIC vector was expressed in E. coli Rosetta-gami 2(DE3)pLysS
cells. Cultures were grown in LB medium supplemented with
ampicillin (100 mgm l
21), and expression was induced by the
addition of 0.5 mM IPTG at 25uC overnight. Harvested cells were
then resuspended in lysis buffer (50 mM NaH2PO4, pH 8.0,
0.3 M NaCl, 5 mM BME, 10 mM imidazole) for lysis at
25,000 psi using a Microfluidizer processor. Next, the lysed
mixture was centrifuged for 50 minutes at 16,000 r.p.m. in a JA-
17 rotor (Beckman Coulter). The supernatant was loaded on a
HisTrap FF crude column (GE Healthcare) with a gradient of
10 mM to 500 mM imidazole in lysis buffer. STAT11–683 was
further purified by size exclusion on a Superdex 200 10/300 GL
(GE Healthcare) in 10 mM Tris-HCl, pH 8.0, 0.3 M NaCl,
5 mM BME. STAT1 cDNA was a gift from Dr. Christopher
Basler (Mount Sinai School of Medicine).
Crystallization and data collection
SUDV1–233 crystallized in 0.1 M HEPES, pH 7.5, 0.1 M
MgCl2, and 8% (v/v) PEG 550 mme. SUDV11–233 crystallized
in 0.1 M HEPES, pH 7.0, 6% MPD, and 15% (w/v) D-(+)-
sucrose. SeMet-derivatized SUDV11–233 crystallized in 0.1 M
HEPES, pH 7.0, 10% MPD, and 1 mM DTT. RESTV11–237
crystallized in 0.1 M Bis-Tris, pH 5.5, 0.2 M NaCl, 8% (w/v)
PEG 3350, and 14% (w/v) D-(+)-sucrose. All crystals were grown
by the hanging-drop vapor diffusion method at 22uC. Crystals
were flash frozen in liquid nitrogen and cryoprotected with their
reservoir solutions supplemented with 40% PEG 550 mme for
SUDV1–233, 40% sucrose for SUDV11–233 and RESTV11–237, and
40% MPD for SeMet-derivatized SUDV11–233.
Both SUDV structures contain one molecule in the asymmetric
unit while RESTV11–237 contains two molecules in the asymmetric
unit. Diffraction data were collected at 100 K on SBC 19ID
(Advanced Photon Source, Argonne National Laboratory) and
BCSB 5.0.2 (Advanced Light Source, Lawrence Berkeley National
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d*Trek [71] (Table 1).
Structure determination and refinement
Experimental phases for SUDV11–233 were generated by MAD
(multiwavelength anomalous diffraction) using Auto-Rickshaw [72].
Five of the seven internal SeMet residues were located and their
locations were verified by hand through a difference Fourier
anomalous electron-density map. Using the experimentally phased
map, the orientations of two helices were determined in the initial
partial model and the rest of the model was built using the MRSAD
(molecular replacementwithsingle-wavelengthanomalousdiffraction
[73]) method in Auto-Rickshaw [72]. The structure of SUDV1–233
was determined by molecular replacement (also Auto-Rickshaw [72])
using SUDV11–233 as the search model. Refinement of both
structures was performed with Phenix.refine [74] in PHENIX [75]
and rebuilding was carried out in COOT [76]. Final rounds of
refinement included TLS parameters [77] for SUDV1–233 and
SUDV11–233. The quality of the structures was validated with
MolProbity [78] and Procheck [79]. 92.7% (SUDV1–233) and 93.1%
(SUDV11–233) of residues are in the most favored region of
Ramachandran plots, with no residues in the disallowed regions.
The final model of SUDV1–233 contains residues 9–106 and 113–232
with residues 113 and 210–213 replaced with alanines. The final
model of SUDV11–233 contains residues 13–61, 71–107, 114–209,
and 212–228. Residue 209 was replaced with alanine.
RESTV11–237 was determined by molecular replacement in
Auto-Rickshaw [72] using SUDV11–233 as the initial search model.
The structure was refined with Phenix.refine [74] in PHENIX
[75] and rebuilt in COOT [76]. Separate NCS restraints and TLS
parameters [77] over the two molecules of VP24 in the
asymmetric unit were used during initial refinement. The quality
of the structure was validated with MolProbity [78] and Procheck
[79]. 92.3% of residues are in the most favored region of
Ramachandran plots and no residues are in the disallowed
regions. The final model contains residues 11–62, 70–203, and
217–231 in molecule A and residues 15–61, 70–108, 113–203, and
216–231 in molecule B. Two residues (203 and 216) in molecule B
were replaced with alanines. Figures were created using PyMol
[80] (Delano Scientific).
Atomic coordinates and structure factors have been deposited in
the Protein Data Bank under the accession codes 3VNE, 3VNF,
and 4D9O for SUDV1–233, SUDV11–233, and RESTV11–237,
respectively.
ELISA
50 ml of each VP24 (SUDV1–233 and EBOV1–233) was bound to
ELISA plates (Corning Costar 3690) at 0.01 mg/ml in 10 mM
Tris-HCl, pH 8.0, 0.3 M NaCl, overnight at 4uC. Plates were then
blocked for one hour at room temperature with 3% BSA. After
washing with PBS containing 0.05% TWEEN 20, 50 mlo f
STAT11–683 with a C-terminal HA-tag was added at 0.03 mg/ml
and allowed to bind for two hours at room temperature. Plates
were again washed, 50 ml of anti-HA (Covance) was added at
1 mg/ml and incubated at room temperature for one hour. After a
third washing step, 50 ml of HRP-conjugated secondary antibody
(Thermo Scientific Pierce) was added and allowed to incubate for
one hour at room temperature. Plates were developed with TMB
Substrate Kit (Pierce) and read at 450 nm. BSA was used as a
negative control.
Deuterium exchange mass spectrometry
Peptide amide hydrogens continuously and reversibly inter-
change with hydrogen present in water. In structured proteins,
most amide hydrogens are infrequently exposed to water, and
exchange only when dynamic fluctuations in the protein structure
transiently reveal them to solvent. Changes in exchange rates after
ligand binding or other protein perturbations allow detection and
localization of protein binding surfaces and conformational
changes. In DXMS, the aqueous phase is supplemented with
deuterated water, so that each exchange event produces a 1
Dalton increase in the mass of exchanged peptide amide protons
in the protein. An initial exchange-dependent labeling step is
performed by adding deuterated water to a solution of the protein
at physiologic pH, and ionic strength. As deuterium-labeling
progresses, aliquots are exchange-‘‘quenched’’ by shifting pH to
2.7 and cooling to 0uC or below, conditions that dramatically slow
further exchange and loss of deuterium label from the protein even
when the protein structure is subsequently disrupted. The site and
amount of deuterium that exchanged onto the protein are
quantified (under continued quench conditions) by rapid dena-
turation, optional disulfide-reduction and digestion by solid-phase
pepsin into overlapping fragments of ,3–15 amino acids. The
perturbed masses of the resulting peptides, and therefore their
deuterium content, are quantified by liquid chromatography- mass
spectrometry.
Prior to the deuteration studies, quench conditions that
produced an optimal pepsin fragmentation pattern were estab-
lished as previously described [52,53,55,56]. For SUDV VP24
(10 mg/ml stock solution) and SUDV VP24-STAT1 (12 mg/ml
stock solution), functional deuteration of proteins was performed
by mixing 1 ml of stock solution with 1 mlo fH 2O buffer (8.3 mM
Tris, 150 mM NaCl, in H2O, pH 7.2) and then diluted into 6 ml
of D2O buffer (8.3 mM Tris, 150 mM NaCl, in D2O, pDREAD
7.2) at 0uC. At 10 s, 100 s and 1000 s, the deuterium exchange
was quenched by adding 12 ml of optimized quench (1.6 M
GuHCl, 0.8% formic acid, 16.6% glycerol) and then samples were
frozen at 280uC. In addition, nondeuterated samples (incubated
in H2O buffer mentioned above) and equilibrium-deuterated
samples (incubated in D2O buffer containing 0.5% formic acid
overnight at 25uC) were prepared. The samples were later thawed
at 5uC and passed over an AL-20-pepsin column (16 ml bed
volume (Sigma)) at a flow rate of 20 ml/min [81]. The resulting
peptides were collected on a C18 trap (Michrom MAGIC C18AQ
0.262) and separated using a C18 reversed phase column
(Michrom MAGIC C18AQ 0.2650) running a linear gradient
of 8–48% solvent B (80% acetonitrile and 0.01% TFA) over
30 minutes with column effluent directed into an LCQ mass
spectrometer (Thermo-Finnigan LCQ Classic). Data were ac-
quired in both data-dependent MS1:MS2 mode and MS1 profile
mode.
SEQUEST software (Thermo Finnigan Inc.) was used to
identify the sequence of the peptide ions. The centroids of the
isotopic envelopes of nondeuterated, functionally deuterated and
equilibrium-deuterated peptides were measured using DXMS
Explorer (Sierra Analytics Inc., Modesto, CA) and then converted
to corresponding deuteration levels [82].
Supporting Information
Figure S1 Additional details of VP24 structures. (a) Crystallized
constructs of VP24 from SUDV and RESTV. The first five
residues of both the N- and C-termini are indicated respectively.
The N-terminal 6xHis-tag was retained throughout purification
and crystallization. (b) Stereo view of SUDV VP24 Faces 1, 2, and
3 in rainbow with blue indicating the N-terminus and red
indicating the C-terminus.
(TIF)
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Sequence alignment of ebola- and marburgviruses. Secondary
structures are assigned according to the crystal structures. Mostly
conserved residues are in white boxes (red characters) while
absolutely conserved residues are in red boxes (white characters).
Grey stars indicate residues with alternate side-chain conforma-
tions observed in electron density maps. (b) Structural alignment
of SUDV1–233 (pink), SUDV11–233 (green), and RESTV11–237
(blue) VP24. SUDV1–233 and SUDV11–233 align with an r.m.s.d. of
0.67 A ˚, and SUDV1–233 and RESTV11–237 align with an r.m.s.d.
of 0.81 A ˚ (CCP4: LSQKAB [85]). Loop residues 63–69 and 210–
211 are visible in their entirety only in SUDV1–233. Loop residues
108–112 are only visible in their entirety in RESTV11–237.
(TIF)
Figure S3 Close-up of Face 1 cavity. (a) Zoomed-in view of the
cavity on Face 1 in RESTV. In RESTV, Tyr 172 is rotated 180u
away from Met 71. (b) Zoomed-in view of the Face 1 cavity in
SUDV. Tyr 172 is rotated toward Met 71. (c) The pairwise VP24-
VP24 interface observed between the two RESTV11–237 in the
asymmetric unit (blue) superposed onto the essentially identical
pair of SUDV1–233 molecules (magenta) formed by a crystallo-
graphic two-fold axis. Residues 51–90 and 167–222 are not
illustrated in order to enhance clarity. Molecular surface
representations of the pairwise interactions (light and dark grey)
are inset. (d and e) Crystal lattice interactions in RESTV and
SUDV. (d) Met10 (a result of construct design) and Val11
(RESTV11–237, molecule 2) form hydrophobic interactions with
the Face 1 cavity of a neighboring RESTV11–237 VP24 (molecule
1). The backbone of Met10 and Val11 hydrogen bonds to the
surrounding residues. (e) Leu10 and Val11 (SUDV1–233, molecule
2) bind into the same pocket of another SUDV1–233 VP24
(molecule 1). Additional hydrogen bonding with surrounding
residues is also illustrated.
(TIF)
Figure S4 Sequence comparison of RESTV, SUDV, and
EBOV mapped onto RESTV11–237.( a) Sequence differences
(red) between RESTV and SUDV and (b) between RESTV and
EBOV (Zaire) are mapped onto Faces 1, 2, and 3. RESTV and
SUDV are 75% identical and RESTV and EBOV are 81%
identical. Circles indicate region shown to interact with karyo-
pherin a1 and regions highlighted by DXMS study. Interestingly,
these regions primarily concentrate on Face 3. To a lesser degree,
two regions, 71–79 and 181–198 are also accessible through Face
1. Residue 50, which has been shown to increase virulence in a
mice serial passage study [50], is located near the region 181–198
and is only accessible through Face 1. Residue names shown as
RESTV to SUDV/EBOV. Green arrows indicate cavities on
Faces 1 and 3.
(TIF)
Figure S5 Gel filtration analysis of full-length VP24. (a) SUDV
(Sudan) VP24 (expressed in E. coli) was separated by size on a
Superdex-200 10/30 prep grade column. Log of molecular mass
standards (670, 413, 158, 44, and 17) plotted with the elution
chromatogram is shown inset within the graph. (b) RESTV
(Reston) and (c) EBOV (Zaire) protein samples (also expressed in
E. coli) were separated by size on a Superdex-200 column with
elution buffer containing 2.5 mM CHAPS. Log of molecular mass
standards (158, 44, and 17) plotted with elution chromatogram is
shown inset. A single peak of VP24 was eluted from each
ebolavirus and corresponds to about 28 kD in mass (monomer).
(d) Similarly, when SUDV VP24, expressed in mammalian
HEK293T cells was separated by size exclusion on a Superdex-
200 10/30 prep grade column, only a monomeric species was
observed. The small peak at ,8 ml corresponds to aggregated
protein eluted in the void volume (much larger than tetramer). Log
of molecular mass standards (669, 443, 150, 75, 44, 29, 13.7, 6.5)
plotted with elution chromatogram is shown inset. The elution
buffer consists of 10 mM Tris-HCl, pH 8.0, and 0.3 M NaCl. (e)
Peak fraction from the S200 column (d) probed by Western blot
with an anti-strep tag antibody. Full-length purified SUDV and
RESTV precipitated at pH 7.4, and 0.15 M NaCl. Therefore, gel
filtration analysis was carried out at pH 8.0 and 0.3 M NaCl
where the proteins remained soluble.
(TIF)
Figure S6 Close-up view of VP24 residue V22. (a) Residue 22
(magenta) is on helix a1 and forms hydrophobic interactions with
neighboring residues E18, L26, L145, S146, M147, and L150. All
SUDV structures contain a valine to alanine substitution at
position 22. (b) Comparison of SUDV (grey) and RESTV (teal)
with residue 22 shown as stick. The loop region connecting helices
a7 and a8 is slightly shifted in RESTV to accommodate the
bulkier isoleucine side chain.
(TIF)
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